Thrivent Financial for Lutherans lowered its position in shares of GSK plc (NYSE:GSK – Free Report) by 6.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 49,864 shares of the ...

GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating reaffirmed by equities research analysts at JPMorgan ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

The London-based pharmaceuticals company said the US Food and Drug administration has approved Blujepa for the treatment of uncomplicated UTIs in female adults and paediatric patients 12 years of age ...